Pharmaceutical

MRNA-2752 by Moderna for Transitional Cell Cancer (Urothelial Cell Cancer): Likelihood of Approval

MRNA-2752 is under clinical development by Moderna and currently in Phase I for Transitional Cell Cancer (Urothelial Cell Cancer).

Dec 22, 2023 - 18:00
MRNA-2752 is under clinical development by Moderna and currently in Phase I for Transitional Cell Cancer (Urothelial Cell Cancer).
Read the original article

Tags:

Previous Article

Imvotamab by IGM Biosciences for Rheumatoid Arthritis: Likelihood of Approval

Next Article

Cadonilimab by Akeso for Esophageal Squamous Cell Carcinoma (ESCC): Likelihood o...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

ASCO24: Akeso’s bispecific vvonescimab faces a rocky road ahead in NSCLC

ASCO24: Akeso’s bispecific vvonescimab faces a rocky ro...

Jun 2, 2024

STAT+: AAFP’s CEO on how to keep primary care doctors in the field

STAT+: AAFP’s CEO on how to keep primary care doctors i...

Dec 23, 2023

FDA clears Pfizer’s meningococcal disease vaccine

FDA clears Pfizer’s meningococcal disease vaccine

Oct 23, 2023